Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
May 04, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- ARCALYST® (rilonacept) launched as the first and only FDA-approved therapy for recurrent pericarditis -- Mavrilimumab Phase 2 severe COVID-19 data demonstrated a reduction in mechanical ventilation...
Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404
May 04, 2021 07:59 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Highest dose cohorts confirm and extend previously-reported 3 mg/kg IV cohort data -- 10 mg/kg IV dose provides full receptor occupancy through Day 71 and complete suppression of TDAR after KLH...
Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients
April 12, 2021 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Primary endpoint achieved: the proportion of patients alive and free of mechanical ventilation at Day 29 was 12.3 percentage points higher with mavrilimumab versus placebo (p=0.1224 met predefined...
Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis
April 01, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis –- ARCALYST now available on prescription basis in the U.S. –- Kiniksa One Connect™ program provides ongoing patient...
Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
March 18, 2021 16:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis -- Commercial launch expected in April 2021 -- Kiniksa launches Kiniksa One Connect™ patient support program --...
Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis
March 02, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, March 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...
Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity
February 23, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Strong execution across pipeline of immune-modulating assets throughout 2020 enables multiple milestones in 2021 -- Rilonacept in recurrent pericarditis granted priority review, with PDUFA goal date...
Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones
January 11, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- PDUFA goal date of March 21, 2021 for rilonacept in recurrent pericarditis -- Data from Phase 2 portion of mavrilimumab Phase 2/3 trial in severe COVID-19 pneumonia and hyperinflammation expected in...
Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021 16:20 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday,...
Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation
December 22, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Early signal of efficacy with trends toward lower mortality and shorter duration of mechanical ventilation in patients treated with mavrilimumab – - Data from the Phase 2 portion of Kiniksa’s...